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PnTx3-4 is a toxin isolated from the venom of the spider Phoneutria nigriventer that blocks
N-, P/Q-, and R-type voltage-gated calcium channels and has great potential for clinical
applications. In this report we used the SUMO system to express large amounts of
recombinant PnTx3-4 peptide, which was found in both soluble and insoluble fractions of
bacterial extracts. We puriﬁed the recombinant toxin from both fractions and showed that
the recombinant peptide showed biological activity similar to the native PnTx3-4. In silico
analysis of the primary sequence of PnTx3-4 indicated that the peptide conforms to all the
criteria of a knottin scaffold. Additionally, circular dichroism spectrum analysis of the
recombinant PnTx3-4 predicted that the toxin structure is composed of approximately 53%
turns/unordered, 31% a-helix and 16% b-strand, which is consistent with predicted model
of the PnTx3-4 knottin scaffold available at the knottin database (http://knottin.cbs.cnrs.
fr). These studies provide the basis for future large scale production and structure-
function investigation of PnTx3-4.
Crown Copyright  2012 Published by Elsevier Ltd. All rights reserved.1. Introduction calcium, potassium, sodium and ligand-gated channelsPeptide toxins obtained from animal venoms are
resourceful compounds to investigate ion channels,
contributing to our understanding of key channels regu-
lating excitability of neurons and cardiomyocytes. Toxins
obtained from the venom of different spiders and sea snails
have provided the framework to understand the structure–
function relationship of a variety of channels includingIPTG, Isopropyl b-D-
e-high performance
e, P.O. Box 5015, 100
19 663 5777x24889;
o.ca (V.F. Prado).
2012 Published by Elsevier(Doering and Zamponi, 2003; Li and Tomaselli, 2004;
Castellino and Prorok, 2000; Lewis et al., 2000; Favreau
et al., 1999). Peptide toxins have also been used as poten-
tial lead compounds for the development of novel thera-
peutic drugs (Alonso et al., 2003; Heading, 2002; Jones and
Bulaj, 2000; Livett et al., 2004; Lewis, 2009). Importantly,
a synthetic neuroactive peptide equivalent to the u-con-
otoxin MVIIA, one of the toxins that target voltage-gated
calcium channels, has been approved for the treatment of
pain (Williams et al., 2008).
Calcium is essential in many physiological mechanisms
including hormone and neurotransmitter release, muscle
contraction and gene transcription; however, excess
calcium inﬂux can generate a cascade of events that cause
cytotoxicity and cell death, making calcium a key player
in ischemic neuronal death (Lau and Tymianski, 2010;Ltd. All rights reserved.
Table 1
Oligonucleotide sequences used to generate the synthetic PnTx3-4 cDNA.
Name Sequence Size (bp)
Tx34SUMOF 50-AATTGGTCTCAAGGTTCTTGTATTAAC
GTTGGTGAT-30
36
Tx3-4SUMOR 50-AATTTCTAGATCAATGGTTTTTTTTAC
AACGTTT-30
34
Tx34A53 50-TGTATTAACGTTGGTGATTTTTGTGAT
GGTAAAAAAGATGATTGTCAGT
GTTGTCGTGATAACGCCTTTTGTTCTTGT
TCTGTTATTTTTGGTTATAAAACCAACTG
TCGTTGTGAAGTT-30
120
Tx34A35 50-AACTTCACAACGACAGTTGGTTTTATA
ACCAAAAATAACAGAACAAGAACAAAAG
GCGTTATCACGACAACACTGACAATCATC
TTTTTTACCATCACAAAAATCACCAACGTT
AATACA-30
120
Tx34B53 50-TGTCGTTGTGAAGTTGGTACCACCGCC
ACCTCTTATGGTATTTGTATGGCCAAACA
TAAATGTGGTCGTCAGACCACCTGTACCA
AACCATGTCTGTCTAAACGTTGTAAAAAA
AACCAT-30
120
Tx34B35 50-ATGGTTTTTTTTACAACGTTTAGA
CAGACATGGTTTGGTACAGGTG
GTCTGACGACCACATTTATGTT
TGGCCATACAAATACC
ATAAGAGGIGGCGGTGGTACC
AACTTCACAACGACA-30
120
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2000). After an ischemic injury, calcium ﬂoods into
neurons throughdifferent channels including voltage-gated
calcium channels, ionotropic glutamate receptors such as
N-methyl-D-aspartate (NMDA) and a-amino-3-hydroxy-5-
metil-4-isoxiazole propionate (AMPA) receptors (Lau and
Tymianski, 2010). Therefore, there is an intensive search
for calcium channel blockers and glutamate receptors
antagonists in the attempt todevelop novel neuroprotective
drugs (Domin et al., 2010; Lipton, 2007, 2006).
The venom of the Brazilian ‘armed’ spider Phoneutria
nigriventer has a number of peptides that are effective
blockers of distinct calcium, potassium and sodium chan-
nels (de Castro Junior et al., 2008; Vieira et al., 2007, 2005;
Cardoso et al., 2003; Carneiro et al., 2003; Vieira et al., 2003;
Reis et al., 2000; Penaforte et al., 2000; Reis et al., 1999;
Kushmerick et al., 1999; Mesquita et al., 1998; Kalapothakis
et al., 1998b, 1998a; Moura et al., 1998; Miranda et al., 1998;
Guatimosim et al., 1997; Prado et al., 1996). Three of these
toxins, named PnTx3-3, PnTx3-4 and PnTx3-6 are voltage-
gated calcium channel blockers that interfere with the
release of glutamate from isolated nerve terminals
(Carneiro et al., 2010; Prado et al., 1996; Souza et al., 2008;
de Castro Junior et al., 2008; Vieira et al., 2007, 2005; Reis
et al., 1999). PnTx3-4 irreversibly inhibits P/Q and N-type
channels, whereas its action against R-type channels is
incomplete and reversible (Dos Santos et al., 2002). PnTx3-3
and PnTx3-6 reversibly and non-speciﬁcally inhibit a broad
spectrum of high-voltage-activated Ca2þ channels, namely
L-, N-, P/Q-, and R-type, with varying potency (Vieira et al.,
2005, 2003; Leao et al., 2000). Recent studies have sug-
gested that these peptides can interfere with processes
related to ischemia-induced glutamate release and
responses topain (Dalmolin et al., 2011; Agostini et al., 2011;
Pinheiro et al., 2009; Souza et al., 2008). These three
peptides decrease glutamate release aswell as neuronal cell
death in retina slices submitted to ischemic injury (Agostini
et al., 2011). Additionally, PnTx3-3 and PnTx3-6 have been
shown to be effective for the control of neuropathic pain in
animalmodelswithno adversemotor effect (Dalmolin et al.,
2011; Souza et al., 2008); PnTx3-4 attenuates neuronal
death and electrophysiological consequences of oxygen and
glucose deprivation in brain slices (Pinheiro et al., 2009);
and PnTx3-6 has analgesic effects in rodent models of
chronic and acute pain (de Souza et al., 2011; Souza et al.,
2008). Therefore, these peptides have the potential to be
used in the therapeutic management of pain and/or as
neuroprotective drugs.
Puriﬁcation of toxins from P. nigriventer’s venom is an
expensive, inefﬁcient and time-consuming process. More-
over, the yield for most toxins present in the venom is very
low (Cordeiro et al., 1993), making it difﬁcult to complete
characterize these peptides. Furthermore, pharmacological
use of these peptides will only be feasible if they can be
produced in large scale. Generation of recombinant toxins
using Escherichia coli is an alternative approach and has been
usedpreviously toobtain functional recombinant toxins from
the P. nigriventer spider (Souza et al., 2008; Carneiro et al.,
2003). In this study, we demonstrate for the ﬁrst time the
functional expression of the toxin PnTx3-4, a valuable scaf-
fold for the development of new neuroprotective drugs.2. Materials and methods
Oligonucleotides used for PCR reactions were synthe-
sized by Sigma. Restriction endonucleases were purchased
from New England Biolabs. The pE-SUMO LIC vector and
SUMO protease I were obtained from LifeSensors Inc.
(Malvern, USA). ORIGAMI (DE3) competent cells were
supplied by Novagen Inc. (Madison, USA). Acetonitrile,
Fura-2AM, glutamate dehydrogenase and Percoll were
obtained from Sigma Chemical Co. (MO, USA).
2.1. Plasmid construction
\Four oligonucleotides named Tx34A53, Tx34A35,
Tx34B53 and Tx34B35 were used as template for the PCR
reaction that produced the coding region for the PnTx3-4
toxin (Table 1). Another two oligonucleotides, Tx34SUMOF
and Tx34SUMOR (Table 1) were used as primers of the same
reaction. Bsa I and Xba I restriction sites (underlined) were
added at the 50 and 30 ends of the DNA, respectively, and
a stop codon (TCA) was also added at the 30 end in order to
stop translation after the last amino acid of the toxin. The
ampliﬁcation reaction contained the template oligonucleo-
tides in a 0.1 mM concentration, the ampliﬁcation primers in
a 1 mM concentration, 250 mM of each deoxynucleotide
triphosphate and 2 U of the thermostable recombinant Taq
polymerase. The reactions were subjected to initial dena-
turation of 4 min at 95 C and subsequent 40 cycles that
consistedof denaturing theDNAat 95 C for1min, annealing
at 55 C for 1 min and elongation at 72 C for 1 min.
The PCR product was puriﬁed using the QIAquick TM
Gel Extraction kit (Qiagen, USA), digested with Bsa I and
Xba I and cloned into pE-SUMO LIC Vector. The plasmid
obtained (6xHis-SUMO-PnTx3-4) encodes a fusion protein
composed of an 18.0 kDa Yeast SUMO protein (Smt3) fused
at the N-terminal with a 6xHis tag and at the C-terminal
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recombinant plasmid was conﬁrmed by automatic
sequencing using the dideoxynucleotide chain-termination
reaction (Sanger et al., 1977).
2.2. Expression and puriﬁcation of the fusion protein
E. coli ORIGAMI (DE3) cells containing pGro7 chaperone
plasmid were transformed with 6xHis-SUMO-PnTx3-4.
An isolated colony was inoculated in 10 mL of LB medium
supplemented with Ampicillin (100 mg mL1) and
Chloramphenicol (20 mg mL1) for cultivation at 30 C
overnight. The culturewas then diluted 100-fold in 1 L of LB
medium (with antibiotics) containing 0.5 mg mL1 of L-
arabinose (for chaperones expression) and cultured to
an OD600 of 0.5–0.8. The expression of the recombinant
fusion protein was induced with 0.6 mM Isopropyl b-D-1-
thiogalactopyranoside (IPTG), overnight, at 18 C with
shaking. Cells were harvested by centrifugation at 5000 g
for 15 min, suspended in 30 mL of Resuspension buffer
(20 mM Tris–HCl, 150 mM NaCl, pH 7.5) containing
protease inhibitor cocktail (CALBIOCHEM), lysed by passing
twice through a French Press (16,000–18,000 psi) and cell
debris were removed by centrifugation.
The recombinant toxin expressed in the supernatant
was puriﬁed by afﬁnity chromatography using a Ni-NTA
agarose resin (Qiagen). After puriﬁcation, elutions were
pooled and dialyzed against 20mM Tris–HCl, 150mMNaCl,
pH 7.5 for 24 h to remove imidazole. To purify the
recombinant toxin present in inclusion bodies, the pellet
obtained after cell lysis was solubilised in a denaturing
buffer (6 M Guanidine-HCl, 100 mM NaH2PO4, 10 mM Tris,
20 mM Imidazole pH 8.0) and incubated for 1 h at RT. The
sample was then centrifuged at 32,000 g for 30min and the
supernatant was puriﬁed by afﬁnity chromatography using
a Ni-NTA agarose resin. The elutions were dialyzed ﬁrst
against 1 M Guanidine-HCl, 0.05 M Tris, 0.15 MNaCl, pH 8.0
and later against 0.1 M Gnd-HCl, 0.05 M Tris, 0.15 M NaCl,
1 mM DTT, pH 8.0.
2.3. Cleavage of 6xHis-SUMO-PnTx3-4 fusion protein and
puriﬁcation of the recombinant PnTx3-4 protein
Samples of 6xHis-SUMO-PnTx3-4 were incubated with
SUMO protease I (1 U:100 mg) for 1 h at 30 C and then
incubated overnight at 4 C to allow complete cleavage.
DTT was added to the reaction to a ﬁnal concentration of
2 mM. The recombinant PnTx3-4 was then puriﬁed from
the 6xHis-SUMO-tag and protease by C8 Reverse Phase-
HPLC using a CH3CN discontinuous gradient in 0.1% TFA.
The absorbance was detected at 214 nm. For the PnTx3-4
isolated from the supernatant, peaks corresponding to the
recombinant toxin were pooled, freeze-dried and stored
at 20 C until needed. For the PnTx3-4 isolated from the
pellet, peaks corresponding to the recombinant toxin
were pooled and treated for refolding.
2.4. Refolding
The pure PnTx3-4 lyophilized was resuspended in 6 M
Gnd-HCl, 50 mM Tris, pH 8.0 and the disulﬁde bonds werereduced with 10 mMDTT for 4 h at RT. Before the refolding,
the DTT was removed from the sample by ﬁltration using
VIVASPIN 6 (3 kDa MWCO). The sample was diluted 20
times into the refolding buffer (550 mM Gnd-HCl, 440 mM
L-arginine, 55 mM Tris, 21 mM NaCl, 0.88 mM KCl, 1 mM
EDTA, 1 mM GSH and 1 mM GSSG, pH 8.2) to a ﬁnal protein
concentration of 0.1–0.2 mg/mL. The recombinant toxin
was added in 5 aliquots with a 2 min interval between each
one to minimize the precipitation of folding intermediates.
The reaction was performed at 4 C for 24 h. For desalting
and to check the refolded recombinant toxin HPLC proﬁle,
the sample was submitted to a C18 Reverse Phase Chro-
matography and the elution samples were lyophilized and
kept at 20 C until needed.
2.5. Protein analysis
All puriﬁcation steps were followed by SDS-PAGE and
Western blotting. Proteins were resolved on 4–20%
gradient gels (Lonza) and stained with RAPIDstain Reagent
(CALBIOCHEM) or transferred to a PVDF membrane (Milli-
pore). The membrane was incubated overnight at 4 C with
anti-P. nigriventer total venom peroxidase antibodies
(1:1250) and developed with ECL Plus Western blotting
Detection System (Amersham).
2.6. Preparation of synaptosomes
All experiments were carried out in incompliance
with the Canadian Council of Animal Care (CCAC) guide-
lines for the care and use of animals. The protocol was
approved by the University ofWestern Ontario Institutional
Animal Care and Use Committee (protocol # 2008-127). All
efforts were made to minimize the suffering of animals.
Cerebral cortices from adult mice (C57BL/6) were isolated
and homogenized in 0.32 M sucrose solution containing
1 mM EDTA and 0.25 mM DTT. The homogenate was
centrifuged at 1000 g for 10min at 4 C and the supernatant
was puriﬁed by discontinuous Percoll gradient centrifuga-
tion as described by (Dunkley et al., 2008) with minor
modiﬁcations. The synaptosomal fractionwas resuspended
in Krebs-Ringer-Hepes (KRH) buffer (124 mM NaCl,
4 mM KCl, 1.2 mM MgSO4, 25 mM HEPES and 10 mM
Glucose and adjusted to pH 7.4) to a ﬁnal concentration of
0.5–1.0 mg/mL for each sample.
2.7. Measurement of [Ca2þ]i
Synaptosomes were loaded with 5 mM fura-2AM (stock
solution 1 mM in DMSO) for measurements of intra-
synaptosomal free calcium concentration [Ca2þ]i. The
quantiﬁcation was performed in a PTI spectroﬂuorimeter
with the ﬂuorescence emission recorded at 510 nm using
340/380 excitation ratio. Synaptosomes were stirred
throughout the experiment andmaintained at 35 C. Native
and recombinant toxins were added to the synaptosomal
suspension 6 min prior to membrane depolarization with
33 mM KCl. Calibration was performed as described by
(Prado et al., 1996) using SDS and EGTA for maximum and
minimum ﬂuorescence values.
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Glutamate release was monitored by measuring the
increase of ﬂuorescence caused by NADPH being produced
in the presence of NADPþ and glutamate dehydrogenase. At
the beginning of each ﬂuorimetric assay, 1 mM of CaCl2,
1mMofNADPþ, and 50U of glutamate dehydrogenasewere
added to the suspension. The excitationwavelengthwas set
at 360 nm and the emission wavelength was monitored at
450 nm. Native and recombinant toxins were incubated
with the synaptosomes for 30 min prior to each assay.
Calcium independent glutamate release was measured by
removing CaCl2 and adding 2 mM EGTA to the preparation.2.9. Statistical analysis
The results were expressed as mean  SEM. The data
were analyzed by one-way analysis of variance (ANOVA)
followed by Tukey test (SigmaSTAT) and Kruskal-Wallis
ANOVA followed by Dun’s multiple comparison test.
3. Circular dichroism (CD)
To get information about the secondary structure of the
toxin PnTx3-4, the CD spectrum of the functional refolded
toxin was collected using a spectropolarimeter Jasco-810
(Jasco Corp.) in water. The temperature was kept at 25 C
and the spectrum was measured from 260 nm to 190 nm
using a 1mm path length cell. A minimum of 10 scans were
done at a time.
To get an estimation of secondary structures present in
the toxin, the data obtained were analyzed using three
different algorithms; CDSSTR, CONTIN and SELCON and two
reference sets for each (Sreerama and Woody, 2000;
Sreerama et al., 1999; Van Stokkum et al., 1990).
4. Results
4.1. PnTx3-4 amino-acid sequence analysis
Fig. 1 shows the amino-acid sequence of the P. nig-
riventer PnTx3-4, toxin and its alignment to two related
peptides from the spider Agelenopsis aperta that, as PnTx3-
4, block N-, P/Q-, and R-type calcium channels. These three
peptides share the same number of amino acid residues
(76-residues) and are highly conserved in their primary
sequence, showing w70% similarity and w50% identity.Fig. 1. Alignment of PnTx3-4 to u-AgaIIIA and u-AgaIIIB, spider peptides that block
sequence alignment was obtained from http://www.ch.embnet.org/software/Clust
residues are colored. Predicted arrangement of disulﬁde bonds for PnTx3-4 and u-A
see Fig. 7) is shown in colored brackets. Disulﬁde bridges in the cystine knot motif a
orange. PnTx3-4 predicted arrangement of disulﬁde bonds correspond to: (C2–C19
interpretation of the references to colour in this ﬁgure legend, the reader is referreInterestingly, the sequence similarity is observed essen-
tially in the amino-terminal end of the proteins (ﬁrst 51
amino acid residues) while the carboxy-terminal end does
not show either similarity in amino acid sequence or
conserved localization of cysteine residues.
4.2. Cloning and expression of the fusion protein
We used the amino acid sequence of PnTx3-4 (Fig. 1),
also named u-Phonetoxin-IIA (Dos Santos et al., 2002;
Cassola et al., 1998), to design a synthetic cDNA. The
nucleotide sequence was chosen following the E. coli codon
usage (Sharp and Li, 1987) to improve expression of the
transcript in prokaryotic cells. The designed PnTx3-4 cDNA
(Fig. 2A) was generated by PCR using six overlapping
oligonucleotides (Table 1; Fig. 2B) and cloned into the pE-
SUMO vector (LifeSensors Inc.). The fusion protein gener-
ated after expression of the pE-SUMO-PnTx3-4 plasmid
included (i) a (His)6 tag followed by (ii) the yeast SUMO
protein (Smt3) and, (iii) the PnTx3-4 peptide (Fig. 2C).
Fusion protein expression was induced in the E. coli
strain ORIGAMI (DE3) by addition of 0.6 mM IPTG. As
shown in Fig. 3A, the 6xHis-Smt3-PnTx3-4 fusion protein
was highly expressed. Although a large amount of the
recombinant protein was present in the soluble fraction
(Fig. 3A, lane 3), considerable amount of the protein was
also present in inclusion bodies (Fig. 3A, lane 2). Because
soluble proteins have the potential to be in their native
conformation, while proteins found in inclusion bodies
need to be denatured and refolded to assume their native
structure, we chose to purify the recombinant PnTx3-4
from supernatant and pellet separately.
4.3. Puriﬁcation of PnTx3-4 from the supernatant
The soluble recombinant 6xHis-SUMO-PnTx3-4 was
puriﬁed from the supernatant by afﬁnity chromatography
using a Ni-NTA agarose resin. Puriﬁed fractionwas dialyzed
for 24 h to remove the imidazole. This puriﬁcation step
isolated the 6xHis-SUMO-PnTx3-4 from most of the bacte-
rial proteins (Fig. 3B, lane 5). To speciﬁcally separate the
PnTx3-4 from its N-terminal 6xHis-SUMO tag we digested
the peptide with SUMO Protease I, which recognizes the
SUMO structure at the N-terminus of the fusion protein and
cleaves the junction (peptide bond linking the last amino
acid residue of SUMO to the ﬁrst amino acid residue of the
recombinant peptide). After digestion, PnTx3-4 was thencalcium ion channels. Percentage of identity is shown based on PnTx3-4. The
alW.html. Gaps () have been introduced to enhance similarities. Cysteine
gaIIIA according to database of structural models (http://knottin.cbs.cnrs.fr;
re shown in green and red. Additional disulﬁde bonds are shown in blue and
); (C9–C25); (C16–C51); (C18–C39); (C27–C37); (C57–C63); (C67–C72). (For
d to the web version of this article.)
Fig. 2. A) Sequence of the synthetic PnTx3-4 cDNA and the codiﬁed product. The restriction sites Bsa I and Xba I (underlined) were added to facilitate cloning. B)
Schematic representation of each oligonucleotide used for the PCR reaction that generated the PnTx3-4 cDNA. C) Representation of the recombinant fusion
protein, the digested fragments and puriﬁed PnTx3-4.
I.A. Souza et al. / Toxicon 60 (2012) 907–918 911puriﬁed by reverse phase chromatography in aWaters HPLC
system using a discontinuous CH3CN gradient. Two main
peaks were observed, one with retention time of about
31 min and the other with retention time of about 41 min
(Fig. 3C). Fractions from each peak were pooled and
analyzed by SDS-PAGE and Western blot. We determined
that the recombinant PnTx3-4 eluted in peak 1, which pre-
sented a band of approximately 8 kDa (Fig. 3D, lane 1) that
could be recognized by a polyclonal antibody raised against
the spider venom (Fig. 3E, lane 2). Approximately 0.6 mg of
pure recombinant PnTx3-4 was reproducibly obtained per
litter of bacterial culture (Table 2).
4.4. Effect of soluble recombinant PnTx3-4 on glutamate
release
To investigate whether the recombinant peptide pre-
sented biological activity analogous to native PnTx3-4, we
tested it initially inaglutamate release assay (deCastro Junior
et al., 2008; Prado et al., 1996). Total glutamate release wasmeasured in mouse cortical synaptosomes depolarized with
33 mM KCl in the presence of 1 mM CaCl2 (Fig. 4A and B).
Addition of 16nMof native PhTx3-4 (puriﬁed from the spider
venom) decreased glutamate release by 36%. Ca2þ removal
from the medium, by adding 2.0 mM EGTA before depolar-
ization with KCl, decreased glutamate release by the same
magnitude (Fig. 4A and B), corroborating previous ﬁndings
that native PnTx3-4 effect is mainly restricted to the Ca2þ-
dependent (exocytotic) glutamate release (de Castro Junior
et al., 2008). Addition of 16 nM of recombinant PnTx3-4
peptide was able to block glutamate release from cortical
synaptosomes as efﬁcientlyas thenative toxin (Fig. 4AandB).
4.5. Effect of soluble recombinant PnTx3-4 on [Ca2þ]i
To further test the biological activity of the recombinant
PnTx3-4 we investigated its effect on blocking Ca2þ chan-
nels involved in glutamate release from cortical synapto-
somes. To do that, we measured changes in cytosolic Ca2þ
in fura-2-loaded synaptosomes (Prado et al., 1996).
Fig. 3. Expression and puriﬁcation of the soluble recombinant PnTx3-4. A) Analysis by Coomassie-stained SDS-PAGE 4–20%. MW: molecular weight standard
(Dual Color Precision Plus). Lane 1: bacterial extract before induction. Lane 2: insoluble proteins extracted from inclusion bodies. Lane 3: soluble proteins from the
supernatant B) Afﬁnity puriﬁcation of the soluble recombinant PnTx3-4. Lane 1: cell extract before induction. Lane 2: cell extract after induction. Lane 3: soluble
proteins recovered after cell breakage. Lane 4: proteins that did not bind to the resin. Lane 5: puriﬁed fusion protein. SDS-PAGE 4–20% gel was stained with the
RAPIDStain reagent (Calbiochem). C) Puriﬁcation of the digested recombinant PnTx3-4 by RP-HPLC using acetonitrile gradient to separate the toxin from its
N-terminal 6xHis-SUMO tag. D) SDS-PAGE 4–20% showing the peaks from the chromatography. Gel was stained using the Silver Stain Plus kit from Bio-Rad. E)
Immunoblot analysis of the recombinant fusion protein. Lane 1: puriﬁed fusion protein. Lane 2: puriﬁed fusion protein digested with SUMO protease I. Lane 3:
Phoneutria nigriventer’s total venom. Antibody: anti-P. nigriventer total venom peroxidase. Arrows indicate bands corresponding to 6xHis-SUMO-PnTx3-4
(26 kDa), 6xHis-SUMO tag (18 kDa) and toxin PnTx3-4 (8 kDa).
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of 1 mM CaCl2 showed a fast increase in internal calcium
concentration (Fig. 4C). Addition of 16 nM of native PnTx3-
4 6 min before KCl depolarization inhibited internal Ca2þ
increase by approximately 30%. Addition of similar
concentration of the recombinant PnTx3-4 peptide to the
preparation also blocked Ca2þ channels, however, the
inhibition of internal Ca2þ increase observed was smaller
(approximately 20% inhibition).
4.6. Puriﬁcation of PnTx3-4 from inclusion bodies
Because the 6xHis-SUMO-PnTx3-4 fusion protein
showed to be highly expressed as inclusion bodies (Fig. 3,lane 2), we chose to improve our puriﬁcation yield by
purifying it from the pellet. To do that, recombinant 6xHis-
SUMO-PnTx3-4 present in the pellet was ﬁrst solubilised in
6 M of Guanidine-HCl (Fig. 5A) and then puriﬁed by afﬁnity
chromatography using a Ni-NTA agarose resin. After
removal of the imidazole by dialysis, the N-terminal tag
was cleaved off by digestion with SUMO protease I (Fig. 5B,
lane 2). The recombinant toxin was puriﬁed by RP-HPLC
and two peaks with retention times of about 32 and
41 min respectively were observed (Fig. 5D and E). The
peak with 32 min retention time presented one band of
8 kDa that could be recognized by a polyclonal antibody
raised against the spider venom (Fig. 5C, lane 1 and 2). This
peptide presented no biological activity when tested in the
Table 2
Puriﬁcation of recombinant PnTx3-4 from E. coli.
Fraction Total protein
(per L of culture)
Supernatant (soluble proteins)a 350 mg
Soluble fusion protein (IMAC puriﬁcation)a 5.3 mg
Digested and puriﬁed (HPLC)c 0.5–0.8 mg
Mass of Gnd-HCI extractb 580 mg
Insoluble fusion protein (IMAC puriﬁcation)a 19.5 mg
Digested and puriﬁed (HPLC)c 3.0 mg
Refoldedc 1.5–2.0 mg
a Determined using Dc Protein assay from Bio-Rad.
b Calculated as weigh difference between pellet of French Press and
pellet of 6 M Guanidine-HCI extraction.
c Determined by A280 nm.
I.A. Souza et al. / Toxicon 60 (2012) 907–918 913glutamate release assay (Fig. 4D and E) indicating that the
peptide was not properly folded.
4.7. Refolding of PnTx3-4 isolated from inclusion bodies
Our next step was to determine the optimized condition
necessary to obtain reliably refolded, biologically active
PnTx3-4. To do that, we incubated the recombinant PnTx3-4
in a strong denaturing buffer (6 M Gnd-HCl, 50 mM Tris,
10 mM DTT, pH 8.0) to completely unfold the protein. After
4 h of incubation at RT, DTT was removed by ﬁltration
(VIVASPIN 6 column; 3 kDa MWCO). The toxin was then
diluted into a refolding buffer to a ﬁnal concentration ofFig. 4. Biological effects of the recombinant PnTx3-4. A and B) Effect of the soluble
release in synaptosomes. Synaptosomes were incubated with the recombinant an
independent glutamate release was measured in the absence of Ca2þ and in the pr
release (nmol/mg of protein). C) Inhibition of calcium inﬂux in depolarized synaptos
KCl after 6 min of incubation with the recombinant and native toxins. The [Ca2
mean  SEM of intrasynaptosomal calcium concentration (nM). D and E) The effec
glutamate release in synaptosomes. ANOVA followed by Tukey test were used to d0.1–0.2 mg/mL. Nine different refolding buffers were tested
(Table 3), ranging from strong to weak denaturing condi-
tions. Refolding was allowed to proceed for 24 h at 4 C,
samples were submitted to RP-HPLC and tested. We
estimated refolding yields by measuring biological activity
using the glutamate release assay as described for experi-
ments in Fig. 4; that is, 16 nM of each refolded peptide was
added to mouse cortical synaptosomes prior to depolar-
ization with 33 mM KCl in the presence of 1 mM CaCl2 and
total glutamate release was measured (Fig. 5F). As our
experiments consistently showed that 16 nM of native
PnTx3-4 or Ca2þ removal from the medium (by adding
2.0 mM EGTA before depolarization with KCl) decreased
glutamate release by the same magnitude (Fig. 4), for these
experiments we compared inhibition of glutamate release
by each refolded peptide to that of EGTA containing buffer.
A refolded sample that presented decrease of glutamate
release similar to that of Ca2þ free medium would
be considered to have 100% of the peptides properly refol-
ded. As can be seen in Table 3 and Fig. 5F, refolding of
PnTx3-4 was suppressed at the lowest and highest dena-
turant concentrations (buffers 1–4, 8 and 9). Highest
PnTx3-4 activity was observed in trial ﬁve, which contained
0.5 M Gnd-HCl, 0.4 M L-arginine, 1 mM GSH and 1 mM
GSSG. Under these conditions, more than 80% of the solu-
bilised PnTx3-4 was refolded. Approximately 1.5–2 mg
of refolded PnTx3-4 peptidewas obtained by using trial ﬁve
conditions (Table 2).recombinant PnTx3-4 compared to the native toxin in Kþ-induced glutamate
d native toxins for 30 min and then depolarized with 33 mM of KCl. Ca2þ-
esence of 2 mM EGTA. The results are shown by mean  SEM of glutamate
omes. Synaptosomes loaded with fura-2AM were depolarized with 33 mM of
þ]i was calculated by ﬂuorimetric assay and the results are expressed as
t of the recombinant PnTx3-4 puriﬁed from inclusion bodies in Kþ-induced
etermine statistical signiﬁcance. *P < 0.001, #P < 0.004.
Fig. 5. Puriﬁcation of the recombinant toxin PnTx3-4 obtained from inclusion bodies. Arrows indicate bands corresponding to 6xHis-SUMO-PnTx3-4 (26 kDa),
6xHis-SUMO tag (18 kDa) and toxin PnTx3-4 (8 kDa). A) SDS-PAGE 4–20% of solubilized inclusion bodies. MW: Molecular weight standard (Dual Color Precision
Plus). B) SDS-PAGE 4–20% of 6xHis-SUMO-PnTx3-4 digested with SUMO protease I. Lane 1: 6xHis-SUMO-PnTx3-4 puriﬁed by afﬁnity chromatography. Lane 2:
6xHis-SUMO-PnTx3-4 digested. C) Immunoblot analysis of the recombinant fusion protein before and after digestion. Lane 1: puriﬁed fusion protein. Lane 2:
puriﬁed fusion protein digested with SUMO protease I. Antibody: anti-P. nigriventer total venom peroxidase. D) Puriﬁcation of the recombinant PnTx3-4. After
digestionwith SUMO protease I, the recombinant toxin was puriﬁed by RP-HPLC using acetonitrile gradient to separate it from the N-terminal 6xHis-SUMO tag. E)
SDS-PAGE 4–20% showing the peaks from the chromatography presented in D. Gel was stained with the RAPIDStain reagent (Calbiochem). F) Effects of refolded
PnTx3-4 in Kþ-induced glutamate release in synaptosomes. Kruskal–Wallis ANOVA followed by Dun’s multiple comparison tests were used to determine
statistical signiﬁcance. *P < 0.05.
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structures for PnTx3-4
To gather information about the secondary structure of
the toxin, we obtained the circular dichroism spectrum of
the functional, refolded, recombinant PnTx3-4 (Fig. 6).
Analysis of the spectrum using the CDSSTR, CONTIN and
SELCON algorithms (Van Stokkum et al., 1990; Sreerama
and Woody, 2000; Sreerama et al., 1999) predicted that
the toxin structure is composed of approximately 53%
turns/unordered, 31% a-helix and 16% b-strand.Fig. 6. Circular dichroism spectrum of the refolded recombinant PnTx3-4.
The concentration of the peptide was 0.5 mg/mL. Data is the average of 3
separate recordings with a minimum of 10 scans each.5. Discussion
In this report we provide a method for expression and
puriﬁcation of recombinant PnTx3-4with native bioactivity.
Identifying ideal conditions for heterologous expression of
functional PnTx3-4 was rather challenging, even more
challenging than ﬁnding the conditions to express other P.
Fig. 7. Predicted spatial structure models for the spider toxins PnTx3-4 and Omega-Agatoxin-IIIA. Ribbon models were drawn using the PyMOL program
according to structural model calculations obtained from the knottin database (http://knottin.cbs.cnrs.fr).
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Kushmerick et al., 1999; Torres et al., 2010; Diniz et al.,
2006). This difﬁculty was probably due to the fact that
PnTx3-4 requires the formation of a larger number of
disulﬁde bonds than the other peptides present in the P.
nigriventer’s venom (Penaforte et al., 2000; Gomez et al.,
2002). That is, seven disulﬁde bonds are necessary to
properly fold PnTx3-4 into its native conformation (Figs. 1
and 7). Initial attempts using expression systems that
generate His-tag-fusion proteins under the control of the
strong T7 promoter (Studier et al., 1990), or the tightly
regulated araBAD promoter (pBAD) (Guzman et al., 1995)
were not successful. These trials either did not generate
fusion proteins in soluble form or the induction of the
protein expressionwas very low (data not shown). Only the
SUMO system was suitable to express large amounts of the
protein, which was found in both soluble and insoluble
form. The SUMO system uses the SUMO protein (Small
Ubiquitin-like Modiﬁer) as a fusion partner, improving the
solubility of the expressed protein (Marblestone et al., 2006;
Malakhov et al., 2004; Butt et al., 2005). In addition, we co-
expressed the chaperones GroEL and GroES to improve the
protein folding process (Thomas et al.,1997), and carried out
the expression in the ORIGAMI (DE3) strain, which has an
oxidizing cytoplasm that provides a better environment for
the proper folding of the toxin (Stewart et al., 1998). It has
been shown that expression of disulﬁde rich peptides in
ORIGAMI (DE3) strain substantially improve the yield of
active proteins puriﬁed (Prinz et al., 1997).Table 3
Refolding conditions.
Buffera Gnd-HCI
(M)
L-arginine
(M)
Redox environment Percent
refolded
1 0 0 2 mM GSH 0.2 mM GSSG NA
2 0 0.4 2 mM GSH 0.4 mM GSSG NA
3 0 0.8 1 mM GSH 1 mM GSSG NA
4 0.55 0 2 mM GSH 0.4 mM GSSG NA
5 0.55 0.4 1 mM GSH 1 mM GSSG 82.5%
6 0.55 0.8 2 mM GSH 0.2 mM GSSG 42.5%
7 1.1 0 1 mM GSH 1 mM GSSG 62.5%
8 1.1 0.4 2 mM GSH 0.2 mM GSSG 12.5%
9 1.1 0.8 2 mM GSH 0.4 mM GSSG 17.5%
a Each buffer contains 55 mM Tris, 21 mM NaCI, 0.88 mM KCI, 1.0 mM
EDTA, pH 8.2.Only part of the recombinant PnTx3-4 was expressed as
a soluble protein. The yield of soluble PnTx3-4 after all the
puriﬁcation steps ranged from 0.5 to 0.8 mg/L, which is in
the same range to what has been reported for other animal
toxins successfully expressed in E. coli (Johnson et al., 2000;
Meng et al., 2011; Che et al., 2009; Souza et al., 2008;
Carneiro et al., 2003). More importantly, the soluble
recombinant protein showed biological activity very
similar to the native PnTx3-4, both in the glutamate release
assay as well as in the measurement of intrasynaptosomal
free calcium concentration. These results indicate that,
similar to the native peptide, soluble recombinant PnTx3-4
is able to block Ca2þ channels involved in glutamate release
from cortical synaptosomes.
Because most of the recombinant PnTx3-4 aggregated
as inclusion bodies we also searched for conditions to
provide efﬁcient refolding of the insoluble recombinant
PnTx3-4. Finding the exact conditions to renature proteins
is usually time-consuming as refolding conditions for
individual proteins vary considerably (Singh and Panda,
2005; Lilie et al., 1998). The basic protocol requires that
puriﬁed inclusion bodies are ﬁrst solubilised with a strong
denaturant, such as guanidine hydrochloride (GdnHCl), to
produce a completely unfolded protein. DTT is also added
to allow reduction of disulﬁde bridges (Fahnert et al., 2004).
The solubilised protein is then diluted or dialyzed into
a refolding buffer to reduce the denaturant concentration,
allowing the protein to refold based on the information
contained in its primary sequence. As the denaturant is
removed, protein aggregation tends to compete with
renaturation therefore, it is crucial to identify the ideal
milieu to recover maximal amounts of native protein.
Several factors inﬂuence renaturation/aggregation during
refolding including protein concentration, concentration of
strong and weak denaturants, pH, temperature, and the
redox environment (Fahnert, 2004; Lilie et al., 1998). Out of
9 different buffer conditions (Table 3) that we tried, only
buffer 5, which contained 0.5 M Gnd-HCl, 0.4 M L-arginine,
1 mM GSH and 1 mM GSSG, allowed proper refolding of
PnTx3-4. Using buffer 5 wemanaged to obtain 1.5–2.0 mg/L
of PnTx3-4 refolded after puriﬁcation from inclusion
bodies. Importantly, the refolded peptide also showed
biological activity very similar to the native peptide. These
results indicate that a balanced molar ratio of reduced to
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provide the appropriate redox potential to allow formation
and reshufﬂing of disulﬁde bonds (Misawa and Kumagai,
1999; Wetlaufer et al., 1987). Proper renaturation of
PnTx3-4 also relied on the presence of non-denaturing
concentrations of the chaotroph GdnHCl. Low concentra-
tions of GdnHCl or urea have been suggested to contribute
to refolding of proteins by slowing down the refolding
kinetics and as a consequence, shifting the competition
between renaturation and aggregation toward the rena-
turation reaction (Fahnert et al., 2004; Lilie et al., 1998).
Additionally, the presence of L-arginine also contributed to
efﬁcient renaturation of PnTx3-4. Although the mechanism
by which L-arginine facilitates renaturation is still not
completely understood, it has been hypothesized that
increased solubilization of folding intermediates might be
involved (Lilie et al., 1998). It is important to note that,
although biological assays indirectly suggest that
recombinant PnTx3-4 and the native PnTx3-4 share similar
properties, we cannot rule out the possibility that minor
structural differences might exist. Future studies including
investigating whether recombinant peptides co-migrate
with the native toxin on HPLC and comparative mass
spectroscopy analysis will be necessary to clarify this issue.
Analysis of the peptide masses of different spider
venoms revealed a bimodal molecular weight distribution,
with 60–70% of the peptides showing 30–50 amino-acids,
and a secondary grouping (less than 10%) showing
peptides 60–80 amino acids long (Escoubas, 2006). Struc-
tural data, although limited, come mainly from the more
abundant short peptides. These studies indicate that short
spider peptides show mainly two different structural
motifs characterized by different cysteine arrangements
and structural features. The most common motif is the
“inhibitor cystine knot” (ICK), also named knottin, with
a consensus sequence of C1X3–7–C2X3–8–C3X0–7–C4X1–4–
C5X4–13–C6, where C represents cysteine residues and X is
any amino acid residue. Disulﬁde bond pairing observed in
all molecules of this type follow the arrangement: C1–C4,
C2–C5, C3–C6. Spatial structure of peptides with ICK motif
is characterized by the presence of a b-hairpin and a pecu-
liar “knot” (origin of its name) (Escoubas, 2006; Vassilevski
et al., 2009). The other less prominent structural scaffold
for short spider toxins is the DDH (disulﬁde-directed beta-
hairpin) motif, with a consensus sequence C1 X5–19 C2 X2
(G/P) X2 C3 X6–19 C4, and arrangement of disulﬁde bonds
C1–C3, C2–C5 (Vassilevski et al., 2009; Escoubas, 2006). It
has been proposed that the DDH motif came earlier in
evolution and the ICK scaffold should be considered to be
a molecular evolution of the DDH motif (Shu et al., 2002;
Wen et al., 2005).
Very few of the longer polypeptides present in spider
venoms have been isolated and sequenced to date. In
addition, the three-dimensional structure of the few long
spider peptides that have been described in the literature
remains undetermined (Vassilevski et al., 2009). PnTx3-4
and the closely related peptide u-Aga-IIIA belong to this
class of peptides (Fig. 1) (Goncaves et al., 2011; de Castro
Junior et al., 2008; Reis et al., 2000; Yan and Adams,
2000). They both are 76 amino acids long, show similar
placement of the cysteine residues, and have overallsequence identity of 70%. These data suggest that the
disulﬁde bonding patterns of the two molecules are likely
to be very similar; however, there has been no NMR study
on either PnTx3-4 or u-Aga-IIIA to deﬁne their three-
dimensional structure.
Recently Kozlov and Grishin (2005), based on the fact
that the majority of spider toxins share similarity in
cysteine arrangement and disulﬁde bridge pattern, devel-
oped a new algorithm that reliably predicts the three-
dimensional structure of the cysteine knot motif based on
primary sequence analysis. Interestingly, these authors
showed that PnTx3-4 and u-Aga-IIIA primary structure
conform to all the criteria of a knottin scaffold (Kozlov and
Grishin, 2005). An automated modeling procedure is now
available for predicting the three-dimensional structure of
knottins (Gracy and Chiche, 2010, 2011) and a database of
structural models for all known knottin sequences is freely
accessible from theweb site http://knottin.cbs.cnrs.fr. Fig. 7
shows the comparison between the knottin database pre-
dicted three-dimensional structures of PnTx3-4 andu-Aga-
IIIA toxins. The two peptides show remarkable structural
similarity (Fig. 7C), not only at the N-terminal end, where
they show high sequence similarity, but also at the C-
terminus, where the peptides do not show amino acid
sequence similarity or conserved localization of cysteine
residues (Fig. 1). Based on the fact that the different steps of
the homology modeling were carefully optimized using
a large set of knottins with known structures and the
accuracy of predicted models was shown to lie between
1.50 and 1.96 Å (Gracy and Chiche, 2010), it is tempting to
propose that the predicted model for PnTx3-4 is a close
representation of the actual structure of the toxin. In fact,
our CD spectrum analysis of the refolded toxin indicated
that PnTx3-4 contains predominantly random coil forma-
tion, which corroborates the predicted model proposed.
The functional expression of recombinant PnTx3-4 and the
structural analysis reported here provide the basis for
future large scale production and structure-function
investigation of this peptide.
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